Abstract
Cervical cancer is the fourth most prevalent cancer in women, which decreases quality of life of the patients. Traditional interventions have failed to improve the overall survival period of patients due to high tumor recurrence after treatment or late diagnosis. Fortunately, preliminary evidence suggests that anti-angiogenic and immunotherapy can efficiently treat against cervical cancer. However, there is no clear evidence on the efficacy of immunotherapy in cervical cancer. Therefore, in this study, we classified cervical cancers in the TCGA dataset using various algorithms and explored the relationship between the immune profile and corresponding sensitivity of the tumors to immunotherapy. Results showed that patients with tumors had higher expression of immunocytes and longer overall survival time. In addition, we build a scoring system based on the immune landscape of the tumor microenvironment of cervical cancer. Tumors with higher scores exhibited better survival outcomes and were more sensitive to immunotherapy. In this study, the immune landscape of cervical cancer was analyzed, and the subtype of cervical cancer based on that difference was proposed. Besides, the subtype of cervical cancer showed different sensitivity to immunotherapeutic response which further confirmed its relationship with tumor immune landscape.
Highlights
IntroductionIt is the leading cause of cancer-associated mortalities (Canfell, 2019)
Cervical cancer is the fourth most prevalent cancer among women
Based on the ESTIMATE algorithm, TME cluster 1 was strongly associated with the estimated, immune, and stromal scores compared with TME cluster 2 (Figure 1E)
Summary
It is the leading cause of cancer-associated mortalities (Canfell, 2019). The median age for patients diagnosed with cervical cancer is 49 years. Cervical cancer lowers the quality of life of the affected persons (Canfell, 2019). It has been established that prolonged infection with human papillomavirus (HPV) type 16 and 18 is a risk factor for cervical cancer (Crosbie et al, 2013). Prophylactic vaccines against high-risk HPV types minimize the risk of developing cervical cancer. Due to the limitations associated with HPV vaccines, reliable therapeutic options for cervical cancer, recurrent or advanced tumors, are required (Shanmugasundaram and You, 2017). As for recurrent cervical cancer, bevacizumab in combination with
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
